All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Protease Inhibitors as Chemotherapeutics

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60461373%3A22330%2F20%3A43934141" target="_blank" >RIV/60461373:22330/20:43934141 - isvavai.cz</a>

  • Alternative codes found

    RIV/61388963:_____/20:00532406

  • Result on the web

    <a href="http://www.chemicke-listy.cz/ojs3/index.php/chemicke-listy/article/view/3668/3604" target="_blank" >http://www.chemicke-listy.cz/ojs3/index.php/chemicke-listy/article/view/3668/3604</a>

  • DOI - Digital Object Identifier

Alternative languages

  • Result language

    čeština

  • Original language name

    Inhibitory proteas jako chemoterapeutika

  • Original language description

    Proteolytic enzymes (peptidases or proteases) are involved in a wide range of human pathologies. Therefore, they represent molecular targets for therapeutic intervention, and protease inhibitors are promising chemotherapeutics. These inhibitory drugs are typically developed as small-molecule compounds that block the protease active site. In this area, pharmaceutical research has achieved a number of successes over the past 30 years, and several dozen protease inhibitors are currently used in clinical practice or are in advanced clinical trials. This review focuses on the most important areas of their application, including the treatment of hypertension, diabetes, hepatitis C, AIDS, Alzheimer&apos;s disease, and cancer.

  • Czech name

    Inhibitory proteas jako chemoterapeutika

  • Czech description

    Proteolytic enzymes (peptidases or proteases) are involved in a wide range of human pathologies. Therefore, they represent molecular targets for therapeutic intervention, and protease inhibitors are promising chemotherapeutics. These inhibitory drugs are typically developed as small-molecule compounds that block the protease active site. In this area, pharmaceutical research has achieved a number of successes over the past 30 years, and several dozen protease inhibitors are currently used in clinical practice or are in advanced clinical trials. This review focuses on the most important areas of their application, including the treatment of hypertension, diabetes, hepatitis C, AIDS, Alzheimer&apos;s disease, and cancer.

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    10400 - Chemical sciences

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2020

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Chemické listy

  • ISSN

    0009-2770

  • e-ISSN

    1213-7103

  • Volume of the periodical

    114

  • Issue of the periodical within the volume

    8

  • Country of publishing house

    CZ - CZECH REPUBLIC

  • Number of pages

    8

  • Pages from-to

    515-522

  • UT code for WoS article

    000558763200002

  • EID of the result in the Scopus database

    2-s2.0-85090661274